With competition heating up in their main earnings driver Copaxone, see this as an answer to increased earnings pressure of the next few years. Either this purchase or the Mylan deal will give them the breathing room they need. Watch what they say on earnings conference call.
would have been nice if Teva made there last offer and if denied then went shopping for other deals, they would be paying more for Agn then they would have for MYL based on earnings
At first it was confirmed by a source, now they say two people. Right now just rumors. Possibly Monday someone confirms there is talks. MYL has been getting dumped and on Monday probably dumped more. Would make a TEVA buyout case of MYL stronger but MYL is being hard headed. MYL will need to consolidate as well to stay relevant since everyone else is.
cause news of AGN splitting into two businesses came out on Friday after hours, so AGN is up on that news. News of Teva talking about buying AGN generics came out on Sat, premarket Teva and AGN will probably be up, MYL down and PRGO up.
These publications -- WSJ, FT, Bloomberg -- when they say confirmed by not one, but two, people familiar with the company's thinking, its fairly "wrong".. also, while not commenting or confirming, no one is denying the rumors either. 2.778 % chance its all untrue! CEO's change their minds, esp when a desperate TEVA offers 35% more than a division is worth on a good day! They should have over turned the Pill and bought a quality MYL business. Any thoughts on where MYL trades Monday?
I was reading article from June 2015 and AGN CEO was saying he doesn't plan on selling the generics side. I'm curious if the rumors are true for TEVA buying AGN generics or not. Right now nothing is confirmed on either side.